TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alphamab Oncology ( (HK:9966) ) has provided an update.
Alphamab Oncology announced changes in its board of directors, with the resignation of Dr. Guo Zijian and Mr. Wei Kevin Cheng as independent non-executive directors, effective June 30, 2025, due to personal and work commitments. The company has appointed Ms. Wong Yan Ki Angel and Dr. Gao Xiang as new independent non-executive directors, bringing extensive experience in accounting, corporate finance, and capital markets, which could positively impact Alphamab’s strategic direction and governance.
More about Alphamab Oncology
Alphamab Oncology is a company incorporated in the Cayman Islands, focusing on the biotechnology and pharmaceutical industry. It specializes in the development of innovative cancer therapies, aiming to address unmet medical needs in oncology.
Average Trading Volume: 3,985,865
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.94B
For detailed information about 9966 stock, go to TipRanks’ Stock Analysis page.